Syngeneic

Description

Syngeneic tumor models target hosts that have fully functioning immune systems in order to support the analysis of interactions between the native immune system and the tumors of interest. These models are essential in the oncology space for testing therapeutic candidates with the objective of host immunomodulation. BioModels has experience with a variety of syngeneic models – both heterotopic and orthotopic – with and without the addition of immunotherapy treatment paradigms. Customizable, translational endpoints could include model characterization, ex vivo cellular assays, tumor microenvironment analysis, and much more. Representative data is shown for heterotopic (subcutaneous) and orthotopic syngeneic tumor models.

  • Advantages: Immunocompetent host, inexpensive animals, tested responsiveness to standard checkpoint/immune-modulating therapies.
  • Disadvantages: Entirely murine models without any human components.
Model Systems
  • C57Bl/6 Mice
  • BALB/c Mice
Standard Readouts
  • Percent weight change
  • Tumor growth kinetics
  • Body condition/activity clinical scoring
Additional Readouts
  • Immunophenotyping
  • Bioluminescent/fluorescent imaging
  • Hematology analysis
  • Cytokine multiplex
  • Ex vivo cellular assays
  • Tumor or host histology
  • Custom assays
Representative DataClick Image to Enlarge
Mean Volume of Syngeneic B16F10-SIY Tumors in a Heterotopic (Subcutaneous) Model of Murine Melanoma with Immune Checkpoint Inhibitor Treatments

B16F10-SIY tumor cells are implanted subcutaneously into the right flank of C57Bl/6 mice. Animals are subject to treatment with vehicle control, Dabrafenib, or anti-PD-L1 mAb, and tumor volumes are monitored throughout the study. Mean tumor volume values per group are shown with AUC analysis.

Whole-Body IVIS Imaging in a Syngeneic Orthotopic Model of Lung Cancer

LL/2-Red-FLuc tumor cells are surgically implanted into the lung parenchyma of C57Bl/6Hsd mice. Animals are subject to treatment with an isotype control or anti-PD-1 mAb, and tumor responses are monitored via imaging with a Caliper IVIS Lumina III to detect luminescence.

Mean Radiant Flux (IVIS) in a mouse Syngeneic Orthotopic Model of Lung Cancer

LL/2-Red-FLuc tumor cells are surgically implanted into the lung parenchyma of C57Bl/6Hsd mice. Animals are subject to treatment with an isotype control or anti-PD-1 mAb, and tumor responses are monitored with whole body imaging to detect luminescence. Whole-body mean radiant flux values are shown with AUC analysis.

Whole-Body IVIS Imaging in a Syngeneic Orthotopic Model of Glioblastoma

GL261-Luc tumor cells are surgically implanted into the intracranial space of C57Bl/6 mice. Animals are treated with vehicle, chemotherapy (temozolomide), or combination therapy (temozolomide + radiation therapy), and tumor responses are monitored via IVIS imaging to detect luminescence.

Mean Radiant Flux (IVIS) n a mouse Syngeneic Orthotopic Model of Glioblastoma

GL261-Luc tumor cells are surgically implanted into the intracranial space of C57Bl/6 mice. Animals are treated with vehicle, chemotherapy (temozolomide), or combination therapy (temozolomide + radiation therapy), and tumor responses are monitored with whole body IVIS imaging to detect luminescence. Whole-body mean radiant flux values are shown with AUC analysis.

Daniel Lichtman

Managing Partner